BC Extra | Oct 23, 2019
Company News

Celiac data persuade Takeda to commit to Cour’s tolerance-inducing therapy

Now that Cour has demonstrated clinical proof of concept, Takeda has exercised its option to license the company’s first-in-class celiac disease therapy that induces tolerance. On Tuesday at the United European Gastroenterology Week meeting in...
Items per page:
1 - 1 of 1